{"id":"W2934686121","doi":"10.1016/s2352-3026(19)30026-2","title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; BC Cancer Agency","funders":"Celgene; MorphoSys; Servier; Innovative Research Group Project of the National Natural Science Foundation of China; F. Hoffmann-La Roche; Genentech; AstraZeneca; Gilead Sciences; TG Therapeutics; Pfizer; Takeda Oncology; Amgen","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Rituximab; Refractory (planetary science); Lymphoma; Oncology; Phases of clinical research; Hodgkin lymphoma; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001627631,0.001339948,0.002511472,0.0003712159,0.0002753293,0.001299707,0.001023307,0.001297784,0.005603154],"category_scores_gemma":[0.001326734,0.0006023165,0.002110453,0.0003977868,0.001079308,0.001304175,0.0005638548,0.002776963,0.0008771335],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009175123,"about_ca_system_score_gemma":0.0008939902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001019013,"about_ca_topic_score_gemma":0.00269422,"domain_scores_codex":[0.9991984,0.0004511466,0.00003641831,0.0001174076,0.00004387452,0.0001527819],"domain_scores_gemma":[0.9993671,0.0002132582,0.0001114993,0.00005281049,0.00002449591,0.0002307814],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9562484,0.003489904,0.001005979,0.0008180087,0.002060854,0.00007503438,0.00008934574,0.0006251193,0.004495409,0.0001798638,0.001232706,0.02967936],"study_design_scores_gemma":[0.9387451,0.05500075,0.003437017,0.0000402302,0.0008286987,0.00006150407,0.00002916005,0.0002032791,0.0003437846,0.0001520779,0.001140998,0.00001731315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825926,0.008908659,0.0006334189,0.001079174,0.0005307497,0.001478484,0.001509205,0.0001147663,0.003152967],"genre_scores_gemma":[0.9857405,0.003916221,0.001379088,0.001429611,0.000487126,0.001570096,0.002003398,0.00004346228,0.00343059],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005603154,"threshold_uncertainty_score":0.01874447,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02909414680174879,"score_gpt":0.3019179139198022,"score_spread":0.2728237671180534,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}